Jfl Life Sciences MD, chairman, board of directors and AGM
NSE: JFLLIFEPharmaceuticals & Biotechnology
Share price at the NSE close on 22 Oct 2026. Previous close ₹10.80.
- Next results date: the board meets on 2 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹34 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 5.0
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 0.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 15.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.47
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 6,000100.0% delivered
Jfl Life Sciences board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.
- Chairperson and managing directorSMIRAL ASHWINKUMAR PATELRelated to the promoter
6 directors3 independent2 executive1 non-executive
- SMIRAL ASHWINKUMAR PATEL · Chairperson and managing directorExecutive · joined Jan 2022 · 60 months as independent · 1 listed board
- TEJAL SMIRAL PATELExecutive · joined Jan 2022 · 60 months as independent · 1 listed board
- MANISHKUMAR JASVANTLAL PATELNon-executive · joined Feb 2022 · 1 listed board · 2 committee seats
- BHAVNA BASANTBHAI SHAHIndependent · joined Feb 2022 · reappointed Aug 2026 · 60 months as independent · 1 listed board · 1 as independent · 2 committee seats, 2 as chair
- SONU LALITKUMAR JAINIndependent · joined Jan 2022 · reappointed Aug 2026 · 60 months as independent · 2 listed boards · 2 as independent · 3 committee seats
- KHYATI BHAVYA SHAHIndependent · joined Aug 2025 · reappointed Aug 2025 · 60 months as independent · 6 listed boards · 6 as independent · 10 committee seats, 4 as chair
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
1 director who left
- AMITA CHHAGANBHAI PRAGADA, left 25 Jul 2025: Others
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 10 Aug 20266 of 6 present3 independent · 9 days in between
- 31 Jul 20266 of 6 present3 independent · 62 days in between
- 29 May 20266 of 6 present3 independent · 52 days in between
- 6 Apr 20266 of 6 present3 independent
Audit Committee
Chair BHAVNA BASANTBHAI SHAH
MANISHKUMAR JASVANTLAL PATEL, SONU LALITKUMAR JAIN
- 10 Aug 20263 of 3 present3 independent · 72 days in between
- 29 May 20263 of 3 present3 independent
Nomination and remuneration committee
Chair BHAVNA BASANTBHAI SHAH
MANISHKUMAR JASVANTLAL PATEL, SONU LALITKUMAR JAIN
No meeting listed in the filing.
Stakeholders Relationship Committee
Chair BHAVNA BASANTBHAI SHAH
MANISHKUMAR JASVANTLAL PATEL, SONU LALITKUMAR JAIN
- 8 Jul 20263 of 3 present3 independent · 87 days in between
- 11 Apr 20263 of 3 present3 independent
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Jun 2026.
- M/s. Doshi & Doshi & Co.Peer-review certificate valid to Jan 2029
1 earlier auditor
- Doshi Doshi & Co.Named in the filing for the quarter to Mar 2025
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Jfl Life Sciences AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Jfl Life Sciences dividend history
Annual general meeting, 25 Aug 2026
931 shareholders on the register on 19 Aug 2026; present: 6 promoters and 10 others; votes counted by Prachi J. Lad / Prachi Lad & Associates.The company's voting result (opens in a new tab)
- To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended March 31, 2026 along with the Directors' Report and Auditor's Report thereonOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
- To appoint a director in place of Shri Manishkumar Jasvantlal Patel (DIN: 09499355), Non-Executive Director, who retires by rotation as Director and being eligible, offers himself for re-appointmentOrdinary99.97% for0.03% against
Against: promoters 0.00% · institutions 0.00% · other public 0.36%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
- Reappointment Of Mr. Smiral Ashwinkumar Patel, As The “Managing Director” Of the Company with Effect From 18th January, 2027 and Ending On 17th January, 2032SpecialPromoters have an interest in it99.97% for0.03% against
Against: promoters 0.00% · institutions 0.00% · other public 0.36%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
- Reappointment Of Mrs. Tejal Smiral Patel (Din: 07391559), As Whole Time Director of The Company with Effect From 18th January, 2027 and Ending On 17th January, 2032SpecialPromoters have an interest in it99.97% for0.03% against
Against: promoters 0.00% · institutions 0.00% · other public 0.36%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
- Reappointment Of Ms. Sonu Lalitkumar Jain (Din: 09387661), As A Non-Executive Independent Director of The Company with Effect From 18th January, 2027 and Ending On 17th January, 2032Special99.97% for0.03% against
Against: promoters 0.00% · institutions 0.00% · other public 0.36%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
- Reappointment Of Ms. Bhavna Basantbhai Shah (Din: 09494548), As A Non-Executive Independent Director of The Company with Effect From 10th February 2027 and ending on 9th February 2032Special99.97% for0.03% against
Against: promoters 0.00% · institutions 0.00% · other public 0.36%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- Yes
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.